Compared to KRAS wildtype, other p.Gly12 mutations and the p.Gly13Asp (G13D) mutation were significantly associated with reduced likelihood of left-sided CRC, 77% and 56% lower, respectively. Here, KRAS is linked to colorectal carcinoma.